DNM2 and cancer: In this cohort of CRPC, 26.2% (38/145) patients with moderate to high Dyn2 expression had PCA cancer-specific mortality versus 15.6% (15/96) of patients with negative or weak Dyn2 expression (P = 0.052) (Fig. 2C).